miR-181a表达水平与ER阳性乳腺癌对内分泌治疗敏感性的关系  

To explore the relationship between miR-181a and endocrine therapy efficiency of ER positive breast cancer

作　　者：闫顺朝[1] 焦昕[2] 李娜[1] 杜扬帆 Yan Shunchao;Jiao Xin;Li Na;Du Yangfan(Department of Oncology,Shengjing Hospital of China Medical University,Liaoning Shenyang 110022,China;Department of Respiratory Medicine,Shenyang Chest Hospital,Liaoning Shenyang 110044,China.)

机构地区：[1]中国医科大学附属盛京医院肿瘤科,辽宁沈阳110022 [2]沈阳市胸科医院呼吸一科,辽宁沈阳110044

出　　处：《现代肿瘤医学》2020年第4期573-577,共5页Journal of Modern Oncology

基　　金：国家自然科学基金项目(编号:81302313);辽宁省自然科学基金指导计划(编号:20170540995);沈阳市中青年科技创新人才支持计划项目(编号:RC170545)

摘　　要：目的:研究miR-181a表达水平与雌激素受体(estrogen receptor,ER)阳性乳腺癌对内分泌治疗敏感性之间的关系。方法:采用梯度递增法诱导乳腺癌他莫昔芬耐药细胞株,利用集落形成实验检测细胞对他莫昔芬的敏感性。利用RT-PCR法检测miR-181a表达的情况,利用KM-plotter分析miR-181表达与乳腺癌患者预后之间的关系。结果:我们成功的诱导了MCF-7他莫昔芬继发耐药细胞株TAM-R。RT-PCR分析结果显示:他莫昔芬继发耐药的TAM-R细胞株及原发他莫昔芬耐药BT474细胞株中miR-181a的表达水平均显著高于对他莫昔芬敏感的MCF-7细胞株。生存分析结果显示:miR-181a的表达水平与ER阴性乳腺癌患者的总生存无关,但在ER阳性乳腺癌中miR-181a表达高的患者总生存明显差于miR-181a低表达者。进一步分析结果显示:在ER阳性但未接受内分泌治疗的乳腺癌患者中miR-181a表达与总生存无关,但在ER阳性且接受过内分泌治疗的乳腺癌患者中miR-181a高表达者总生存显著差于miR-181a低表达者。结论:miR-181a高表达ER阳性乳腺癌患者对内分泌治疗敏感性差,miR-181a可能是预测ER阳性乳腺癌对内分泌治疗敏感性的指标。To investigate the expression of miR-181a and endocrine-therapy sensitivity of estrogen receptor(ER)positive breast cancer.Methods:We constructed tamoxifen-resistant MCF-7 cell line using gradient incremental method.Cells proliferation was measured using colony formation assay.The expression of miR-181a was determined by RT-PCR.The prognostic value of miR-181a in breast cancer was analyzed using Kaplan-Meier Plotter.Results:We successfully constructed a cell line resistant to tamoxifen(TAM-R).RT-PCR results showed that the expression of miR-181a was higher in tamoxifen induced and primary resistance cell lines than tamoxifen sensitive cell line.High expression of miR-181a predicted significantly poorer overall survival(OS)in ER-positive but not ER-negative breast cancer.Further analysis showed that high expression of miR-181a was associated with poorer OS in endocrine-therapy treated ER-positive breast cancer but not in ER-positive breast cancer without endocrine-therapy treatment.Conclusion:High expression of miR-181a predicted less sensitive to endocrine therapy in ER positive breast cancer.miR-181a might be a promising predictor of the efficacy of endocrine therapy.

关 键 词：miR-181a 乳腺癌 内分泌治疗 疗效 

分 类 号：R737.9[医药卫生—肿瘤]